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14 Introduction
15 XenQ5 on is a colorless, odorless, tasteless, mono-atomic, and in-
16 ert gas with a relative molecular weight of 131.3, and the em-
17 pirical formula is Xe. Xenon is an extremely rare gas that rep-
18 resents no more than 0.0875 ppm in the atmosphere; this fea-
19 ture led the discoverers William Ramsay and Morris Travers to
20 name it xenon from the Greek word “ξενοσ” (xenos) for
21 stranger or foreign. Because of xenon’s rarity, it is extremely
22 expensive to produce from the residue left from air separation
23 units that are used to produce oxygen; therefore, its commercial
24 applications have been limited to high-priced applications such
25 as the ultimate “clean gas” in the electronics/semi-conductor
26 industry, an ion propellant for space travel, and a bright lighting
27 source, and for medical applications, notably anesthesia, imag-
28 ing, and neuroprotection following acute ongoing injury.
29 In this review, the authors trace the development of xenon
30 for medical applications from the physico-chemical properties
31 to the initial preclinical studies, and conclude in randomized
32 clinical trials (RCTs).
33 Inert but Biologically Active
34 Because xenon is enshrouded by five filled electron shells, it is
35 incapable of covalent bonding and forming adducts under
36biological conditions as electrons cannot be donated or accept-
37ed. However, because of xenon’s relatively high polarizability
38[1], with a value of 4 compared with 0.2 for helium, it can
39form dipoles and has an affinity for amino acid residues sur-
40rounding preformed hydrophobic cavities thereby changing
41the functional properties of neighboring proteins by London
42dispersion forces. In this manner, xenon has been shown to
43have activity on many proteins, governed mostly by the size
44and shape of xenon atoms.
45Because of its chemical non-reactivity, xenon is not
46biotransformed, which results in two important features
47governing its future clinical use. Most xenobiotic drugs are
48converted into metabolites that may be toxic; as xenon is not
49metabolized, the dangers posed by toxic metabolites are obvi-
50ated. Furthermore, xenon in the inspired and expired gases are
51identical, permitting recirculation of exhaled xenon and there-
52by limiting the need for a fresh supply of this scarce resource.
53Xenon for Anesthesia
54Xenon was reported to have anesthetic properties in 1951 [2]
55and comes closest to exhibiting all of the ideal properties of an
56inhaled general anesthetic (Table 1). Compared with nitrous
57oxide, the other non-potent gaseous anesthetic, xenon is 1.5
58times more potent; xenon is more suitable than nitrous oxide
59for anesthesia because of its lower blood/gas solubility and the
60consequent extremely rapid inflow and washout from the
61body. Despite this, xenon is infrequently used as an anesthetic
62even though European market authorization has been in effect
63for more than a decade; low utilization is attributed to the high
64cost involved in manufacturing this rare gas from the atmo-
65sphere. Therefore, the expense of using xenon as an anesthetic
66for routine adult surgery appears not to be justified given the
67available alternatives [3].
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68 Drugs produce the anesthetic state via interaction with re-
69 ceptor targets which potentiate inhibitory neurotransmission
70 and/or inhibit excitatory neurotransmission [4]. Xenon is
71 thought to exert anesthetic action by potent non-competitive
72 inhibition of the excitatory NMDA receptors [5] through an
73 action at the binding site of the co-agonist, glycine [6]. Xenon
74 also exerts potent effects on the neuronal background potassi-
75 um channels including two-pore domain potassium channels
76 such as TREK and TASK, which modulate neuronal excitabil-
77 ity [7], and on ATP-sensitive potassium channels [8].
78 The first reported clinical experience with xenon for anes-
79 thesia was published in 1951 by Cullen and Gross, who re-
80 ported on two patients who underwent surgical procedures
81 (orchiectomy in an 81-year-old man and fallopian tube liga-
82 tion in a 38-year-old woman who was 24-h postpartum) while
83 receiving a xenon–oxygen (80:20) mixture to achieve the first
84 plane of the third stage of anesthesia [2]. Induction was com-
85 pleted within 5 min and both patients maintained normal
86 blood pressure, pulse rate, and pulse character and had good
87 color throughout the procedures. Within 2 min of
88 discontinuing xenon, both patients were oriented to time,
89 place, and person; several hours later, they were able to recol-
90 lect information given to them at this time. Since then, numer-
91 ous clinical studies have investigated the effects of xenon in
92 humans.
93 Safety and tolerability information regarding xenon for in-
94 halation stemmostly from published literature describing clin-
95 ical studies investigating the anesthetic properties of xenon
96 gas, and the publications contain only summary information.
97 In aggregate, the literature suggests that administration of xe-
98 non, as a general anesthetic, to patients both with and without
99 cardiovascular disease is associated with hemodynamic
100stability that is unparalleled in critical care settings. Side ef-
101fects identified in the literature that are frequently associated
102with the use of xenon gas for inhalation as a general anesthetic
103include raised intracranial pressure [9], bradycardia [3], and
104nausea and vomiting [10]. Although bradycardia is a safety
105concern identified for xenon anesthesia, if heart rate slows to
106the point that systemic blood pressure decreases, then standard
107positive chronotropic agents such as anti-muscarinic agents
108(e.g., glycopyrrolate or atropine) and β1 adrenergic agonists
109(e.g., isoproterenol) can be administered to reverse it. Xenon is
110not known to interfere with oxygenation, but in an oxygen and
111xenon mixture, the greater the percentage of inhaled xenon
112administered to a subject, the lower the fraction of inspired
113oxygen that can be administered. Under circumstances in
114which lung oxygenation is compromised (e.g., from pulmo-
115nary edema), a higher fraction of inspired oxygen may be
116required to prevent arterial hypoxemia.
117Xenon has a favorable pharmacokinetic (PK) profile for
118anesthesia with fast induction and emergence, which is inde-
119pendent of the duration of exposure. This PK effect is attrib-
120utable to its low blood-gas partition coefficient of 0.115 [11],
121which is significantly lower than those of other inhalational
122anesthetics (nitrous oxide, 0.47; sevoflurane, 0.65; desflurane,
1230.42). As xenon is excreted by the lungs with no biotransfor-
124mation by the renal or hepatic systems, it may prove to be the
125anesthetic of choice in certain circumstances when liver or
126kidney function decrements.
127Xenon has an oil/water solubility coefficient of 20, which is
128the highest coefficient of all noble gases, and it is the only
129noble gas with anesthetic properties at atmospheric pressures.
130The physico-chemical properties of xenon are detailed in
131Table 2.
132Cardiovascular Effects of Xenon in Patients
133Without Cardiac Diseases
134In 1990, Lachmann and associates published a randomized
135double-blind trial comparing the efficacy and potency of xe-
136non with those of nitrous oxide, with special focus on the
137cardiovascular and respiratory systems [12]. The authors
t1:1 Table 1 Properties of an
“ideal” inhalation agentt1:2 Obtainable in pure form at a reasonable
cost
t1:3 Inherently stable
t1:4 Not biotransformable
t1:5 Lacks organ-specific toxicity
t1:6 Minimal cardiorespiratory effects
t1:7 Non-flammable
t1:8 Low blood-gas partition coefficient for
rapid uptake, elimination, and
titratability
t1:9 Sufficiently potent allowing an enriched
inspired oxygen concentration
t1:10 Lacks long-term adverse effects with
chronic exposure
t1:11 Lacks unpleasant smell and irritation to
airway
t1:12 Possesses analgesic and hypnotic
properties
t1:13 Readily reversible central nervous system
effects with no stimulation
t2:1Table 2 Physico-
chemical properties:
Ostwald solubility
coefficients of xenon at
37 °C
t2:2Ostwald solubility coefficients (mL gas/
mL liquid) at 37 °C
t2:3Water/gas 0.075
t2:4Oil/gas 1.8
t2:5Blood/gas 0.115
t2:6Oil/water 20
t2:7Muscle/liver/kidney 0.10
t2:8Adipose tissue 1.3
t2:9Brain, gray substance 0.13
t2:10Brain, white substance 0.23
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138 concluded that xenon is a more potent anesthetic than nitrous
139 oxide in suppressing response to surgical stimuli and main-
140 taining hemodynamic stability. Lachmann’s group also com-
141 pared the effect of xenon and nitrous oxide on the neurohu-
142 moral response and hemodynamics of 32 ASA class I–II pa-
143 tients, with the same protocol as described above [13]. The
144 investigators concluded that xenon has more favorable hemo-
145 dynamic, neurohumoral, and antinociceptive properties than
146 nitrous oxide. Luttropp and associates investigated the effects
147 of xenon on in vivo cardiac function using transesophageal
148 echocardiography and hemodynamic measurements [14]. The
149 fractional area in a short-axis view of the left ventricle at the
150 level of the papillary muscles remained unchanged, suggest-
151 ing that xenon anesthesia had no adverse effect on myocardial
152 function as well as hemodynamics. The first multicenter ran-
153 domized control trial, involving 224 patients in six centers,
154 compared xenon/oxygen with isoflurane/nitrous oxide anes-
155 thesia and concluded that xenon anesthesia is as safe and
156 effective as the isoflurane/nitrous oxide regimen, with the ad-
157 vantage that xenon exhibited more rapid recovery [15]. Also,
158 significantly fewer xenon-anesthetized patients required ino-
159 tropic support than the isoflurane group. In a single center
160 study involving 160 patients, the hemodynamic effects were
161 compared between those randomized to receive either xenon
162 or propofol [16]. While systolic blood pressure was well
163 maintained after induction with xenon at near baseline levels,
164 propofol caused a significant post-induction decline in pres-
165 sure that persisted throughout maintenance of general anes-
166 thesia. Heart rates were significantly lower in the patients who
167 received xenon. In a multicenter study involving 252 patients
168 scheduled for elective non-cardiovascular surgery, hemody-
169 namic stability, including transesophageal echocardiography,
170 was compared between patients randomized to receive either
171 xenon or isoflurane [17]. While isoflurane decreased the myo-
172 cardial contractile index, no such change was noted in the
173 xenon-anesthetized patients, leading the authors to opine that
174 xenon enables cardiovascular stability.
175 Cardiovascular Effects of Xenon in Patients With
176 Cardiovascular Diseases
177 Ten patients after coronary artery bypass graft surgery (per-
178 formed on cardiopulmonary bypass) were randomized to re-
179 ceive either propofol or xenon for sedation while being venti-
180 lated in the ICU [18]. The patients were crossed over to the
181 alternative sedative after some hours. Compared with propofol
182 sedation, xenon sedation did not change the heart rate or blood
183 pressure; left ventricular stroke work index was similar.
184 Effects of xenon on hemodynamics in patients scheduled
185 for coronary artery bypass graft surgery have also been
186 assessed [19]. Statistically significant differences were found
187 between the two groups’ mean arterial pressure (MAP), frac-
188 tional area change of the left ventricle, and end-diastolic area
189of the left ventricle. Xenon decreased the MAP and fractional
190area change significantly less and increased end-diastolic area
191significantly more than nitrous oxide. In a safety and feasibil-
192ity study involving 20 patients undergoing coronary artery
193bypass surgery, xenon, at varying concentrations (0%, 20%,
19435%, and 50% v/v), was administered while on cardiopulmo-
195nary bypass [20]. Despite theoretical concerns about expan-
196sion of gas bubbles, the cerebral embolic load, measured by
197middle cerebral artery Doppler, was no higher in patients who
198received xenon. Troponin levels tended to be lower 24 h after
199surgery in patients who received xenon. Twenty-six patients
200scheduled for implantation of an internal cardioverter-
201defibrillator were randomized to receive either xenon or
202propofol (both with remifentanil) for maintenance of general
203anesthesia [21]. Most of these patients had heart failure from
204ischemic heart disease or dilated cardiomyopathy. In contrast
205to propofol, surgical patients maintained on xenon had no
206changes in either the MAP or the left ventricular ejection
207fraction.
208Central Nervous System Effects of Xenon
209Volunteers (n = 12) were randomized to receive general anes-
210thesia with xenon or propofol and the cerebral metabolic rate
211was assessed with the positron emission tomography (PET)
212ligand 18F-fluorodeoxyglucose [22]. The xenon-exposed vol-
213unteers had cerebral metabolic rates globally reduced by 26%
214compared with those exposed to propofol alone. In another
215study, using 15O-labeled water, the regional cerebral blood
216flowwas monitored by PETscanning during xenon anesthesia
217in nine volunteers [23]. Xenon statistically significantly de-
218creased the regional cerebral blood flow in several of the gray
219matter areas studied while regional cerebral blood flow in-
220creased by 22.1% (± 13.6%) in the white matter. A follow-
221up PET study, involving five healthy subjects, assessed re-
222gional cerebral blood flow and regional cerebral glucose me-
223tabolism using 15O-labeled water and 18F-labeled
224fluorodeoxyglucose, respectively [24]. In general, the regional
225reduction in cerebral metabolism was greater than the regional
226decrement in cerebral blood flow. Luttrop et al. [14] investi-
227gated the effects of inhalation of 65% xenon on cerebral blood
228flow velocities, using Doppler sonography in 17 ASA class I
229patients undergoing abdominal surgery; they found that cere-
230bral blood flow velocity was unchanged during the first 5 min
231of xenon anesthesia, but was significantly increased in the left
232and right, middle, and the right anterior cerebral arteries after
23315 and 30 min. In addition, Giller et al. [25] noted that admin-
234istration of 25%, 30%, or 35% of xenon for 5 min to normal
235volunteers resulted in an increase in cerebral blood flow, mea-
236sured by Doppler velocity, in 85% of subjects and a decrease
237in cerebral blood flow in 15% of subjects. These findings are
238in contrast to the findings of the PET studies described in the
239preceding paragraph. Reasons for these discrepancies could
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240 be differences in the patient populations (i.e., healthy volun-
241 teers versus patients undergoing surgery), differences in the
242 duration of xenon administration, and differences in the meth-
243 odology used to assess blood flow. In a trial involving supple-
244 mentation of therapeutic hypothermia with administration of
245 xenon to neonates suffering from hypoxic ischemic encepha-
246 lopathy, Azzopardi and colleagues reported a significant re-
247 duction in seizure activity in patients randomized to receive
248 30% xenon [26].
249 Neuroprotection
250 Xenon is thought to exert neuroprotective action by acting as an
251 antagonist at NMDA receptors. Excessive entry of calcium,
252 mediated by NMDA receptors, triggers biochemical cascades
253 that ultimately lead to neuronal cell death. NMDA-induced neu-
254 rotoxicity is through “excitotoxicity” from overactivation of
255 NMDA receptors that underlies the acute neuronal injury ob-
256 served following insults such as stroke, cardiac arrest, and trau-
257 matic brain injury. NMDA receptor antagonists are neuropro-
258 tective in in vitro and in vivo brain injury models [27].
259 Following the discovery that xenon inhibitsQ6 NMDA receptors
260 [5], it was shown that xenon could protect neuronal cell cultures
261 against injury induced by NMDA, glutamate, or oxygen-
262 glucose deprivation [28]. The same study showed xenon to be
263 neuroprotective in vivo against neuronal injury caused by sub-
264 cutaneous injection of N-methyl (D, L)-aspartate in rats.
265 Subsequently, this finding was corroborated by Petzelt et al.,
266 in an in vitro model of hypoxia [29] and in an in vivo model
267 of stroke [30]. Other NMDA receptor antagonists such as ni-
268 trous oxide, ketamine, and dizocilpine (MK-801) have intrinsic
269 neurotoxicity, but xenon not only appears to be devoid of these
270 neurotoxic effects but also ameliorates the injury produced by
271 other NMDA antagonists [31]. Furthermore, xenon upregulates
272 the transcription factor hypoxia inducible factor 1 alpha (HIF
273 1α) and its downstream cytoprotective effectors including eryth-
274 ropoietin [32, 33]. Xenon has now been shown to afford neuro-
275 protection in a variety ofmammalian in vitro and in vivomodels
276 and meets the Stroke Treatment Academic Industry Roundtable
277 recommendation for proceeding to clinical trials [34].
278 Phase II Clinical Trial in Out-of-Hospital Cardiac Arrest
279 Patients
280 Based upon successful animal studies investigating the effects
281 of xenon in the setting of cardiac arrest [35, 36] and because of
282 the synergistic interaction between xenon and therapeutic hy-
283 pothermia [37, 38], the Xe-Hypotheca trial (NCT 00879892;
284 May 2009–September 2014) was initiated at a single academ-
285 ic site (University of TurkuHospital, Finland) to determine the
286 feasibility and cardiac safety of inhaled xenon when added to
287 therapeutic hypothermia for successfully resuscitated out-of-
288hospital cardiac arrest (OHCA) patients [39]. Feasibility was
289established after the first 36 patients were randomized to re-
290ceive either therapeutic hypothermia alone (n = 18) or thera-
291peutic hypothermia in combination with xenon by inhalation
292(n = 18), with a target concentration of at least 40% xenon for
29324 h. In the xenon group, the median end-tidal xenon concen-
294tration was 47% and duration of xenon inhalation was 25.5 h.
295Xenon did not induce significant conduction, repolarization,
296or rhythm abnormalities. Median dose of norepinephrine dur-
297ing hypothermia was 2.95 mg in xenon-treated patients and
2985.30mg in patients treated with therapeutic hypothermia alone
299(p = 0.06). Heart rate was statistically significantly lower in
300xenon-treated patients than that in patients treated with thera-
301peutic hypothermia alone (p = 0.04). From the initial results of
302this trial, the investigators concluded that xenon treatment in
303combination with hypothermia is feasible and has favorable
304cardiac features in OHCA patients. The Xe-Hypotheca trial
305was extended to a second site in 2013 (University of Helsinki
306Hospital, Finland) with an expanded cohort; the effect of xe-
307non on ischemic white matter damage was assessed by frac-
308tional anisotropy from diffusion tensor magnetic resonance
309imaging (MRI) [40]. Neurological outcome and mortality at
3106 months were also assessed. A total of 224 patients were
311screened for eligibility. One hundred and ten OHCA patients,
312aged 24–76 years, were randomized to receive either hypo-
313thermia treatment alone for 24 h (control group, n = 55) or
314inhaled xenon, administered to achieve an end-tidal xenon
315concentration of at least 40%, combined with hypothermia
316(33 °C) for 24 h (xenon group, n = 55). The primary endpoint
317was severity of ischemic white matter brain injury as evaluat-
318ed by fractional anisotropy from diffusion tensor MRI; MRIs
319were scheduled within 16 h after rewarming of a patient (rang-
320ing between 36 and 52 h after OHCA). Secondary endpoints
321were neurological outcome, assessed with cerebral perfor-
322mance category score (from 1 = conscious, alert, able to work,
323might have mild cognitive deficit, to 5 = death) and modified
324Rankin Scale (score from 0 = no symptoms at all to 6 = death),
325mortality at 6 months, and complication rate within 7 days of
326post-CA. However, the trial was not powered to detect statis-
327tically significant differences in clinical efficacy (i.e., mortal-
328ity at 6 months and neurological outcome) between groups.
329The primary endpoint was assessed in the complete case pop-
330ulation. Survival at 6 months and complication rate were an-
331alyzed in the intention-to-treat population. Kaplan–Meier sur-
332vival curves and a Cox proportional hazards model were used
333to compare mortality at 6 months between groups.
334Of the randomized patients, six patients in the control
335group and seven patients in the xenon group were missing
336MRI data and were excluded from the complete case popula-
337tion. The mean (±SD) global fractional anisotropy value of all
338voxels in the xenon group (0.433 [± 0.028]) was significantly
339different than that in the control group (0.419 [± 0.033]) (p =
3400.03). The age-, gender-, and site-adjusted mean global
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341 fractional anisotropy values were 3.8% higher in the xenon
342 group than those in the control group (adjusted mean differ-
343 ence 0.016 [95% CI, 0.005 to 0.027]; p = 0.006). The severity
344 of observed widespread injury was demonstrated; on average,
345 41.7% of the white matter tracts, including major commissur-
346 al, associative, and projection fibers, were significantly more
347 severely injured in the control group than in the xenon group.
348 These fibers are involved in multiple important cognitive
349 functions such as attention, memory, language, emotions, au-
350 ditory, visual and executive processing, and motor functions
351 of the body.
352 At 6 months, 75 patients (68.2%) were alive and able to
353 provide follow-up data. In ordinal analysis of modified
354 Rankin Scale, median (interquartile range) value was 1 (0 to
355 6) in the xenon group and 1 (0 to 6) in the control group
356 (median difference = 0 [95% CI, 0 to 0]; p = 0.68). The
357 Kaplan–Meier survival estimate (panel A)Q7 after 6 months
358 was 27.7% (15/55 patients) in the xenon group and 34.5%
359 (19/55 patients) in the control group (adjusted hazard ratio =
360 0.49 [95% CI, 0.23 to 1.01]; p = 0.053) (Fig. 1).
361 It was concluded that among comatose survivors of
362 OHCA, treatment with inhaled xenon combined with hypo-
363 thermia resulted in less white matter damage, as measured by
364 fractional anisotropy of diffusion tensor MRI, than treatment
365 with hypothermia alone. In contrast, there was no statistically
366significant difference between groups in neurological out-
367comes or mortality at 6 months. However, the study was un-
368derpowered to detect a statistically significant difference in
369clinical outcome due to the rarity of severe neurological im-
370pairment in long-term survivors after CA; about 90% of CA
371patients who are alive at the 6-month follow-up have experi-
372enced a good neurological outcome (cerebral performance
373category 1–2). While there was no statistically significant dif-
374ference in neurological outcomes or mortality at 6 months,
375unpublished data demonstrates that there was a trend to a
376survival benefit.
377A predefined secondary objective was to assess the effect of
378inhaled xenon on myocardial ischemic damage [41]. Troponin-
379T levels were measured at hospital admission, and at 24 h, 48 h,
380and 72 h post-CA. Among comatose OHCA patients, inhaled
381xenon combined with hypothermia resulted in less severe myo-
382cardial injury than with hypothermia alone, as demonstrated by
383the significantly reduced release of troponin-T.
384Rates of serious adverse events (SAEs) in the xenon group
385were not significantly different from the rates of SAEs in the
386standard of care group [40]. SAEs seen in both the xenon and
387standard of care groups include status epilepticus, acute kid-
388ney injury (in the “risk,” “injury,” or “failure,” RIFLE catego-
389ries), pulmonary edema, ventricular fibrillation, ventricular
390tachycardia, atrial fibrillation, coronary stent thrombosis,
Fig. 1 Whole-brain fiber tractography of fractional anisotropy. Fractional
anisotropy (FA) is a scalar value representing directionality of water
diffusion. White matter damage leads to a loss of microstructural
organization that can be quantified by the loss of directionality in the
diffusion of water molecules in the white matter tracts. Using data from
a diffusion tensor imaging sequence of an MRI scan performed within
72 h of rewarming, panels a–f represent sequential ascending horizontal
planes of the major tracts in the brain. The visualization presents the
results of the voxel-wise tract-based spatial statistics analysis of FA
values between the xenon group and the control group. Voxels with
significantly (p < 0.05, family-wise error corrected for multiple
comparisons) higher fractional anisotropy values in the xenon group
were identified and are shown in red in the statistical visualization (i.e.,
41.7% of all 119,013 analyzed voxels), whereas areas in which there were
no significant difference in fractional anisotropy values between the
groups are shown in green (modified from reference [40])
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391 sepsis, pneumonia, multi-organ failure, adult respiratory dis-
392 tress syndrome, and subarachnoid hemorrhage SAEs only ob-
393 served in the xenon group included bradycardia treated with
394 pacemaker (n = 1 event) and serious bleeding (gastrointesti-
395 nal, n = 1 event). SAEs only observed in the standard of care
396 group included third-degree atrioventricular block (n = 1
397 event), carotid dissection (n = 1 event), carotid thrombosis
398 (n = 1 event), and serious bleeding (intracranial, n = 1 event).
399 Conclusion and Potential Future Applications
400 Xenon exhibits many features of a putative neuroprotective
401 agent with an ideal pharmacokinetic profile for use following
402 acute neurological injury. Studies involving several different
403 acute neurological injury models in a variety of animal species
404 from four laboratories have consistently demonstrated the
405 neuroprotective efficacy of xenon even when administered
406 as long as 6 h following neurological injury. The mechanisms
407 for neuroprotection appear to involve (i) antagonism of the
408 NMDA receptor whose activation is pivotal for the excitotoxic
409 damage that follows neurologic injury, and (ii) upregulation of
410 HIF 1α and the resulting cytoprotection from erythropoietin, a
411 downstream effector of the transcription factor.
412 A phase 2 RCT (Xe-Hypotheca) demonstrated significant-
413 ly less white matter brain damage, as reflected by higher glob-
414 al fractional anisotropy values, in subjects randomized to re-
415 ceive xenon by inhalation during the 24-h period of targeted
416 temperature management.
417 The stage is now set for a pivotal phase 3 RCT,
418 XePOHCAS (NCT03176186), to determine the efficacy
419 (using endpoints of good functional outcome and survival at
420 30 and 90 days), safety, and cost-effectiveness of xenon, at a
421 dose of 50% of 1 atmosphere, in the management of post-
422 cardiac arrest syndrome patients. The trial is likely to report
423 its outcome in 2021 or before depending on the interim anal-
424 ysis at the halfway point of the 1436-patient trial to be con-
425 ducted in 7 countries in Europe and North America.
426 In the event that xenon exhibits neuroprotective efficacy in
427 the XePOHCAS trial, then subsequent trials are likely to be
428 conducted in other acute neurological injury settings including
429 stroke and traumatic brain injury. As with the XePOHCAS trial,
430 the maximal dose of xenon is likely to be restricted to ≤ 50% of
431 1 atmosphere as these patients may also have lung injury that
432 will require an FiO2 of no less than 0.5 to avoid hypoxemia.
433 A further clinical application may be in pediatric surgical
434 settings to obviate the occurrence of anesthetic-induced devel-
435 opmental neurotoxicity (AIDN). For AIDN, xenon may be
436 particularly effective both by reducing exposure to high con-
437 centrations of neurotoxic volatile anesthetics by virtue of xe-
438 non’s anesthetic properties and because the neurotoxicity may
439 be obviated by xenon’s neuroprotective properties.
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